Abstract Leber hereditary optic neuropathy and autosomal dominant optic atrophy are the two most common inherited optic neuropathies. The latter has been associated with mutations in the OPA1 and OPA3 genes. To date, only six families with OPA3-associated dominant optic atrophy have been reported. In order to identify additional families, we performed Sanger sequencing of the OPA3 gene in 75 unrelated optic neuropathy patients. Affected individuals from two families were found to harbour the c.313C>G, p.(Gln105Glu) change in heterozygous state; this genetic defect has been previously reported in four dominant optic atrophy families. Intra-and interfamilial variability in age of onset and presenting symptoms was observed. Although dominant OPA3 mutations are typically associated with optic atrophy and cataracts, the former can be observed in isolation; we report a case with no lens opacities at age 38. Conversely, it is important to consider OPA3-related disease in individuals with bilateral infantileonset cataracts and to assess optic nerve health in those whose vision fail to improve following lens surgery. The papillomacular bundle is primarily affected and vision is typically worse than 20/40. Notably, we describe one subject who retained normal acuities into the fifth decade of life. The condition can be associated with extraocular clinical features: two affected individuals in the present study had sensorineural hearing loss. The clinical heterogeneity observed in the individuals reported here (all having the same genetic defect in OPA3) suggests that the molecular pathology of the disorder is likely to be complex.
Introduction
Inherited optic neuropathies are a clinically and genetically heterogenous group of disorders associated with selective loss of retinal ganglion cells. Clinically, they are characterised by colour vision deficits, visual field defects and, typically, bilateral, symmetrical and irreversible visual loss [1] . Mitochondrial dysfunction appears to play a central role in the pathophysiology of these disorders and inheritance can be mitochondrial [MIM #535000] or monogenic; autosomal dominant (for example [MIM #165500] and [MIM #165300]), autosomal recessive (for example [MIM #612989]) and Xlinked [MIM %311050] subtypes have been described. Notably, certain types of inherited optic neuropathy form part of clinical syndromes that include additional ocular or nonocular features [2] .
Defects in the OPA3 gene [MIM *606580] have been previously associated with both recessive and dominant optic neuropathy. Biallelic OPA3 mutations cause 3-methylglutaconic aciduria type III [MIM #258501], a recessive neuro-ophthalmological syndrome, most prevalent amongst individuals of Iraqi-Jewish origin and classically characterised by the following triad: (i) bilateral optic atrophy diagnosed in the first decade of life, (ii) a movement disorder (ataxia or extrapyramidal dysfunction) of variable severity beginning in the first or second decade of life and (iii) increased urinary excretion of 3-methylglutaconic acid [3] [4] [5] [6] [7] [8] . Disease-causing OPA3 variants inherited in an autosomal dominant fashion can also cause optic neuropathy. This is often associated with congenital/infantile lenticular opacities; hearing loss and neurological symptoms can also be features of the disorder. Autosomal dominant OPA3-related disease is less common than the recessive form, and only six families have been identified to date. The following dominant diseaseassociated variants have been reported [NCBI Reference Sequence: NM_025136.3]: c.277G>A, p.(Gly93Ser); c.313C> G, p.(Gln105Glu) (recurrent mutation); c.10_11insCGCCCG, p.(Val3_Gly4insAlaPro) [9, 10] .
The OPA3 gene is composed of at least three exons that are alternatively spliced to produce two major transcripts: OPA3A (exon 1 plus exon 2a; encodes the 179 amino acid isoform b; NCBI Reference Sequence: NM_025136.3) and OPA3B (exon 1 plus exon2b; encodes the 180 amino acid isoform a; NCBI Reference Sequence: NM_001017989.2). Although cDNA studies indicate ubiquitous expression of both transcripts, OPA3A is much more strongly expressed in most tissues, including the brain [11] . Notably, the OPA3A amino acid sequence appears to be more conserved in evolution and yet no human disease has been associated with mutations in the OPA3B-specific exon 2b [7, 11] . At the subcellular level, OPA3 localises predominantly to the mitochondrial inner membrane, and although its function remains unclear, previous studies have suggested involvement in the regulation of mitochondrial morphology [10, 12] .
In the present study, we report clinical and genetic findings in two families with dominant OPA3-related optic neuropathy. The phenotypic spectrum of the disorder is broadened and intra-and interfamilial variability is discussed.
Materials and methods
Initially, 74 unrelated individuals with a presumed diagnosis of inherited optic neuropathy (mean age, 43 years; range, 24 to 66 years) were tested for OPA3 mutations using Sanger sequencing of the three exons and flanking intron-exon boundaries of the OPA3 gene (primers and conditions available on request). All these subjects were previously screened and excluded for (i) defects in the OPA1 gene ([MIM *605290], the major cause of dominant optic neuropathy [2, 13] ; this did not include testing for large insertions/deletions using Multiplex ligation-dependent probe amplification or MLPA) and (ii) the three primary mitochondrial mutations associated with Leber hereditary optic neuropathy ([MIM #535000]; m.11778G>A, m.14484 T>C and m.3460G>A). Subsequently, members of an additional family with suspected dominant optic atrophy and cataracts were recruited and tested for OPA3 mutations in a similar fashion.
Clinical assessment of individuals with OPA3-related disease included detailed history, best corrected logarithm of the minimum angle of resolution (logMAR) visual acuity, dilated fundus examination and optic disc imaging. Optical coherence tomographs of the optic nerve head were obtained with the spectral-domain Cirrus platform (Carl Zeiss Meditec, Dublin, CA, USA) in two cases. An audiogram was performed in three patients. Informed consent was obtained from all participants, and all investigations were conducted in accordance with the principles of the Declaration of Helsinki. Institutional Review Board (IRB)/Ethics Committee approval was obtained from the Multicentre Research Ethics Committee (MREC).
Results
Three OPA3 coding variants that have not been previously reported in publicly available databases (1,000 genomes project database, National Heart, Lung, and Blood Institute Ex- Table S1 ). Each of these changes was detected in the heterozygous state in a sporadic case, and it was not possible to perform segregation analysis to support their pathogenicity.
Also, none of these alters the amino acid sequence of isoform b (OPA3A) and we, therefore, consider them to be variants of unknown significance.
In addition to these variants, a heterozygous c.313C>G, p.(Gln105Glu) change (only affecting OPA3A, the transcript encoding the 179 amino acid isoform b; [NCBI Reference Sequence: NM_025136.3]) was identified in an individual with a diagnosis of dominant optic atrophy (subject C1; Fig. 1a ). This sequence alteration is the most common OPA3 mutation associated with dominant disease as it was previously identified in four families segregating optic atrophy [9, 10] ; therefore, no further evidence was needed to confirm that this is a functional variant. The proband as well as his affected sister (subject C2) and daughter (subject C3) presented in the first years of life with nystagmus and abnormal optic disc appearance. The clinical findings are detailed in Table 1 .
The same disease-associated variant, c.313C > G, p.(Gln105Glu), was detected in all three affected members of a family (Fig. 1b ) that were recruited and tested for OPA3 mutations at a later time. Colour disc images and clinical findings are presented in Fig. 1c and Table 1 , respectively.
Discussion
Dominant OPA3-related disease is a clinically heterogeneous disorder (Table 1) ; some patients present with poor visual behaviour and nystagmus from birth (for example subject C1), while others remain asymptomatic until later in life (for example, subject M2). The optic neuropathy is characterised by primary involvement of the papillomacular bundle and has similarities with that observed in individuals with OPA1 mutations [14] . Age of onset is in the first two decades of life (Table 1) , and although comprehensive longitudinal data are lacking, patients typically experience a slowly progressive, symmetrical decrease in vision [9, 10] . Visual acuity is usually Table 1 for clinical findings of all tested individuals as well as subject M4 (IV:2). c Right and left optic disc appearance of an individual with a confirmed OPA3 mutation (subject M1) showing pallor of the neuroretinal rim, which is more marked temporally. Left optic nerve appears more affected than the right and has optic disc excavation in addition to the temporal pallor. d Left optic disc appearance and pattern of retinal nerve fibre layer (RNFL) thinning in an individual with a confirmed OPA3 mutation (subject M2). Sparing of the nasal, superior and inferior peripapillary quadrants is observed. The RNFL profile for each eye is superimposed on the normal distribution percentiles. The normal distribution indices are colour-coded: (i) red <1 %, (ii) yellow <5 %, (iii) green <95 % and (iv) white >95 % The term cataracts is used to denote bilateral crystalline lens opacities. Variants are annotated according to the NCBI Reference Sequence NM_025136.3 (OPA3 isoform b) F female, M male, VA visual acuity, logMAR logarithm of the minimum angle of resolution (equivalent), BE both eyes, NA not available, s/n sensorineural, AV arteriovenous worse than 0.3 logMAR, and it is of interest that one subject in the present series had preserved acuity and no visual complaints at age 41 (subject M2; 0.1 logMAR right, 0.2 logMAR left; Table 1 and Fig. 1d ). Previous reports have shown that peripheral visual fields are spared and that colour vision is impaired [9, 10] . Nevertheless, loss of colour discrimination is variable and without a systemic axis [10] . Subject M3 reported dyschromatopsia only in the right eye, in keeping with findings from colour vision testing with the Ishihara plates (right eye 4 of 17 plates; left eye 16 of 17 plates). On fundus examination, temporal optic disc pallor was the most common finding in the present cohort, although diffuse pallor involving the whole neuroretinal rim and optic disc excavation are not unusual [9, 10] . Notably, subject M1 who was referred to the clinic after a routine eye test at age 60 revealed an enlarged cup-to-disc ratio (0.8) in the left eye (Fig. 1c) ; an erroneous initial diagnosis of glaucoma was made as consideration was not given to the fact that she had infantile-onset cataracts operated at age 35. Furthermore, subject M4 had a healthy optic disc appearance in the right eye and only subtle pallor in the left eye at age 14. In such equivocal cases, measurement of retinal nerve fibre layer thickness with optical coherence tomography can be helpful (for example, Fig. 1d ). Future imaging studies in patients with OPA3-related disease are expected to provide further insights.
Crystalline lens opacities (i.e. cataracts) are observed in most affected individuals [9, 10] . Nevertheless, a patient with a heterozygous p.(Val3_Gly4ins2) mutation and no cataracts at age 52 has been reported by Grau and colleagues [10] . Only one of the seven patients reported here had no clinical history of cataract: subject C3 was examined at age 38 and no lens opacity was detected. It is worth highlighting that a number of patients with OPA3-related disease presented with bilateral lens opacities at birth or in early childhood (including subject M4 who was only noted to have optic atrophy after lens extraction at age 15); therefore, OPA3 mutations should be in the differential in cases of bilateral infantile-onset cataract, and it is important to assess optic nerve function and health before concluding about the likely amblyogenicity of the lens opacities.
Ocular OPA3-related disease often occurs in parallel with extraocular clinical features. Reynier and colleagues reported affected members of a family with a heterozygous p.(Gly93Ser) change in OPA3 to have mild neurological signs including spasticity and extrapyramidal dysfunction [9] . Subsequently, Grau and colleagues reported four individuals with a heterozygous p.(Val3_Gly4ins2) change to have hearing loss. Expression analysis of OPA3 in murine cochlear tissue was consistent with the notion that auditory neuropathy can be an extraocular feature of OPA3-related disease [10] . Notably, two affected individuals from the present cohort had sensorineural hearing loss (Table 1) ; hearing impairment has been previously described in a patient with the same genetic defect [10] . Clinicians should be vigilant to the development of such a complication and audiograms should be performed in all patients with OPA3-related disease at least once.
All OPA3 families with dominant disease reported to date have affected individuals in two or more generations and disease-associated variants appear to be highly penetrant (Fig. 1a,b, [9, 10] ). The p.(Gln105Glu) change identified in both families reported here has been previously shown to be a recurrent mutation [10] ; it was not possible to perform haplotype analysis in subjects from the present cohort, and thus, the possibility of a recent common ancestor in the two families cannot be excluded. The p.(Gln105Glu) change affects an amino acid in a predicted coiled-coil structure (Uniprot), but it is unclear how this common cause of OPA3-related disease affects mitochondrial function and/or structure.
Findings from this and other studies [9, 10] suggest that dominant OPA3-related disease is associated with significant intra-and interfamilial phenotypic variability. Any attempt to draw genotype-phenotype correlations would therefore be highly speculative and secondary genetic factors are likely to be the basis for the observed clinical heterogeneity; a similar conclusion has been reached for the much commoner OPA1-associated optic neuropathy [14] . Expansion of the phenotypic spectrum of OPA3-related disease has led to greater understanding of the condition and the risks of developing extraocular complications. However, it is still unclear what disease mechanism explains multisystem tissue involvement and future studies on the pathogenesis of the disorder are expected to provide important insights.
